Atgen Co. Ltd. | Ownership
Companies that own Atgen Co. Ltd.
Korea Investment Value Asset Management Co., Ltd.
3,463,910
14.02%
16,499
3.94%
09/11/2018
Mirae Asset Global Investments Co., Ltd.
1,738,476
7.04%
222,815
0.21%
02/28/2018
The Vanguard Group, Inc.
428,107
1.73%
157
0%
07/31/2018
BlackRock Fund Advisors
347,318
1.41%
0
0%
09/05/2018
BlackRock Advisors (UK) Ltd.
336,009
1.36%
0
0%
09/06/2018
Norges Bank Investment Management
69,632
0.28%
10,880
0%
12/31/2017
Charles Schwab Investment Management, Inc.
18,024
0.07%
0
0%
09/06/2018
TIAA-CREF Investment Management LLC
10,573
0.04%
0
0%
03/31/2018
State Street Global Advisors Ltd.
1,520
0.01%
0
0%
09/05/2018
Korea Investment Management Co., Ltd.
762
0%
762
0%
01/31/2017
| Address |
1st & 6th Floor, Health Care Park
Seongnam-si GY 13605
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.nkvue.com |
| Updated |
09/14/2018 |
| ATGen Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The company was founded on January 14, 2002 and is headquartered at Seongnam-si, South Korea. |
